Abstract
Background Rapid closure of open wound, either temporarily or perpetually, is recognized as the standard of care in patients with thermal burns. Human cadaveric allograft and simple genetically modified porcine xenografts are not able to provide enough durable time for extensively burned patients. A selective germline genome edited pig (SGGEP) skin xenograft, Xeno X skin, would be a valuable candidate to the clinical options.
Methods In an ongoing investigator-initiated clinical trial in patients with thermal burns, the efficacy and safety of cryopreserved Xeno X skin grafts of SGGEP for burned patients were evaluated. Each patient received surgical grafting with a skin xenotransplant and wild type pig extracellular matrix (wpECM) in a side-by-side manner for in-situ comparison.
The primary outcome measures of xeno-skin grafts included Xeno X skin safety and tolerability, as well as the quality and duration of temporary barrier function yielded by Xeno X skin grafts (as determined by Baux score). Seven parameters included in the analysis were vascularization, pigmentation, thickness, relief, pliability, surface area and the overall opinion, with each calculated on an independent 0-10 scale.
Results A total of 16 burned patients completed the trial. All the patients tolerated Xeno X skin grafts well and no advent events were observed. In all cases, Xeno X skin grafts were vascularized and fully adherent, they also exhibited better overall outcomes than those of wpECM. Xeno X skin grafts survived for at least 25 days without a need of any immunosuppressive drug, well consistent with our earlier preclinical studies in non-human primates.
Conclusion Xeno X skin grafts of SGGEP did not incur any signs of local and systemic safety issues, and in the meanwhile provided a high quality and long duration of temporary barrier function for burned patients. This is a major milestone in the xenotransplant field, indicating that genome-edited organ xenotransplant has become a clinical reality.
Competing Interest Statement
LZ received the research funding from: the National Natural Science Foundation of China [81660364, 81760343], Jiangxi Provincial Department of Education Research Program Major Project (171352), Science and Technology Planning Project of Jiangxi Health Commission (20191025, 202130131). GZ received the research funding from: National Key R&D Program of China (2017FA105202), the Natural Science Foundation Grants (82072480), the Shenzhen Science and Technology Innovation Committee (GJHZ20180928155604617). XZ received the research funding from the National Natural Science Foundation of Guangdong Province-Major Fundamental Research Fostering Program, China (2017A030308004),Science and Technology Program of Guangzhou, China (201804020011),National Nature Science Foundation of China (32071341). YY received the research funding from: Shenzhen Institute of Synthetic Biology Scientific Research Program (Grant No. DWKF20190010, JCHZ20200005). FC received the research funding from: the Shenzhen Institutes of Advanced Technology Innovation Program for Excellent Young Researchers (Y9G075). GW, YY are inventors on patents and patents applications related to this article. GW,JH,QS,WL,HY are employee at Gen Heal Pharma, a privately owned company developing therapeutic xenotransplant. GZ,XZ,LL have participated in a Gen Heal Pharma Advisory Board related to Xeno X Skin. All others have no potential conflict of interest.
Clinical Trial
ChiCTR2100055076
Funding Statement
LZ received the research funding from: the National Natural Science Foundation of China [81660364, 81760343], Jiangxi Provincial Department of Education Research Program Major Project (171352), Science and Technology Planning Project of Jiangxi Health Commission (20191025, 202130131). GZ received the research funding from: National Key R&D Program of China (2017FA105202), the Natural Science Foundation Grants (82072480), the Shenzhen Science and Technology Innovation Committee (GJHZ20180928155604617). XZ received the research funding from the National Natural Science Foundation of Guangdong Province-Major Fundamental Research Fostering Program, China (2017A030308004),Science and Technology Program of Guangzhou, China (201804020011),National Nature Science Foundation of China (32071341). YY received the research funding from: Shenzhen Institute of Synthetic Biology Scientific Research Program (Grant No. DWKF20190010, JCHZ20200005). FC received the research funding from: the Shenzhen Institutes of Advanced Technology Innovation Program for Excellent Young Researchers (Y9G075).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Institutional Review Board of the First Affiliated Hospital of Nanchang University.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
we just correct author list
Data Availability
All data produced in the present study are available upon reasonable request to the authors
